- All sections
- C - Chemistrymetallurgy
- C07F - Acyclic, carbocyclic, or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
- C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Patent holdings for IPC class C07F 9/6561
Total number of patents in this class: 1499
10-year publication summary
|
117
|
105
|
122
|
116
|
80
|
101
|
94
|
109
|
122
|
81
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Gilead Sciences, Inc. | 2032 |
111 |
| The Regents of the University of California | 19961 |
34 |
| Achillion Pharmaceuticals, Inc. | 164 |
25 |
| Samsung Display Co., Ltd. | 34907 |
23 |
| Rigel Pharmaceuticals, Inc. | 538 |
20 |
| Merck Sharp & Dohme LLC | 3751 |
20 |
| LG Chem, Ltd. | 17635 |
19 |
| Sarepta Therapeutics, Inc. | 384 |
19 |
| Novartis AG | 10744 |
13 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 829 |
13 |
| Cipla Limited | 465 |
12 |
| Shionogi & Co., Ltd. | 852 |
12 |
| LT Materials Co., Ltd. | 408 |
12 |
| Bristol-myers Squibb Company | 4880 |
11 |
| Glaxosmithkline Biologicals S.A. | 1651 |
10 |
| Centre National de La Recherche Scientifique | 10464 |
9 |
| Cancer Targeted Technology LLC | 28 |
9 |
| Les Laboratoires Servier | 537 |
9 |
| ViiV Healthcare UK (No. 4) Limited | 22 |
9 |
| Eisai R&D Management Co., Ltd. | 1232 |
9 |
| Other owners | 1100 |